Putnam Allstate Advisor Plus
Putnam Global Health Care Subaccount
The subaccount seeks capital appreciation.
- Highlights
- Performance
- Holdings
- Expenses
Fund description
The subaccount seeks to capitalize on the strength of the health-care sector, targeting companies of all sizes. Holdings encompass an array of industries, including pharmaceuticals, health-care services, and biotechnology. The fund seeks companies that offer strong long-term growth prospects, regardless of their size.
Sales story
Investing in the health-care sectorA dynamic sector: From biotech to pharmaceuticals, the fund seeks out companies that profit from the global demand for health care.A range of companies: The fund invests worldwide in businesses at different stages of growth, from rapidly growing newer companies to established global corporations.Actively managed: Unlike passively managed ETFs, Putnam global sector funds combine rigorous fundamental research and disciplined quantitative analysis with macroeconomic views.
Management team
- Michael J. Maguire, CFA (Investing since 2001)
- Isabel Buccellati (Investing since 1994)
Daily pricing as of 07/20/17
| with optional enhanced death benefits | ||
|---|---|---|
| Unit Value | $22.531331 | $21.941059 |
| Unit Value Change | 0.107273 | 0.104373 |
The fund concentrates its investments in one region or in one sector and involves more risk than a fund that invests more broadly. Variable annuities are long-term investments designed for retirement purposes. Withdrawals prior to age 59 1/2 may be subject to a 10% IRS penalty.
Growth investing targets companies with above-average earnings that may be subject to price volatility if earnings expectations are not met.
‡ Lipper is an industry research firm whose rankings are based on total return performance, vary over time, and do not reflect the effects of sales charges. Past performance is not indicative of future results.
Performance as of 06/30/17
| Annualized Performance | Last Quarter | Year to Date |
1 yr. | 3 yrs. | 5 yrs. | 10 yrs. | Life of subaccount |
|---|---|---|---|---|---|---|---|
| Restated performance | |||||||
| Unit Value | 5.25% | 14.03% | 8.48% | 5.98% | 14.63% | 7.60% | 5.07% |
| Standardized | -2.75% | 6.03% | 0.48% | 3.55% | 13.93% | 7.60% | 5.07% |
| With optional enhanced death benefit | |||||||
| Unit Value | 5.21% | 13.94% | 8.31% | 5.82% | 14.46% | 7.44% | 4.91% |
| Standardized | -2.79% | 5.94% | 0.31% | 3.39% | 13.75% | 7.44% | 4.91% |
| Actual performance | |||||||
| Unit Value | 5.25% | 14.03% | 8.48% | 5.98% | 14.63% | 7.60% | 4.41% |
| Standardized | -2.75% | 6.03% | 0.48% | 3.55% | 13.93% | 7.60% | 4.41% |
| With optional enhanced death benefit | |||||||
| Unit Value | 5.21% | 13.94% | 8.31% | 5.82% | 14.46% | 7.44% | 4.25% |
| Standardized | -2.79% | 5.94% | 0.31% | 3.39% | 13.75% | 7.44% | 4.25% |
| Cumulative Performance | Last Quarter | Year to Date |
1 yr. | 3 yrs. | 5 yrs. | 10 yrs. | Life of subaccount |
|---|---|---|---|---|---|---|---|
| Restated performance | |||||||
| Unit Value | 5.25% | 14.03% | 8.48% | 19.05% | 97.92% | 108.10% | 158.17% |
| Standardized | -2.75% | 6.03% | 0.48% | 11.05% | 91.92% | 108.10% | 158.17% |
| With optional enhanced death benefit | |||||||
| Unit Value | 5.21% | 13.94% | 8.31% | 18.50% | 96.42% | 104.95% | 150.73% |
| Standardized | -2.79% | 5.94% | 0.31% | 10.50% | 90.42% | 104.95% | 150.73% |
| Actual performance | |||||||
| Unit Value | 5.25% | 14.03% | 8.48% | 19.05% | 97.92% | 108.10% | 111.29% |
| Standardized | -2.75% | 6.03% | 0.48% | 11.05% | 91.92% | 108.10% | 111.29% |
| With optional enhanced death benefit | |||||||
| Unit Value | 5.21% | 13.94% | 8.31% | 18.50% | 96.42% | 104.95% | 105.78% |
| Standardized | -2.79% | 5.94% | 0.31% | 10.50% | 90.42% | 104.95% | 105.78% |
Annual Performance at NAV
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| -2.20% | -18.40% | 23.99% | 0.83% | -2.76% | 20.31% | 39.40% | 25.60% | 6.06% | -12.77% |
| With optional enhanced death benefit | |||||||||
| -2.35% | -18.53% | 23.80% | 0.67% | -2.90% | 20.12% | 39.19% | 25.41% | 5.90% | -12.90% |
Restated performance
|
|
||||||||||||
With optional enhanced death benefit
|
|
||||||||||||
Unit values and performance information shown apply to the specific annuity product listed, not the underlying Putnam Variable Trust fund. This information should not be used by investors who hold an interest in Putnam Variable Trust funds through a different annuity or other variable product. The unit values and performance of other variable products that offer Putnam Variable Trust funds may be higher or lower due to product charges and expenses or other factors.
Data is historical. Past performance is no guarantee of future results. More recent returns may be less or more than those shown. Investment return and principal value will fluctuate, and you may have a gain or a loss when you sell your units.
Returns shown for the subaccounts for periods before their inception are derived from the historical performance of the underlying fund, adjusted to reflect the mortality, expense risk, and surrender charges applicable to this product and do not factor in the annual $30 contract maintenance fee. Additional riders and options for insurance-related charges will increase expenses and lower returns. Please see the prospectus for details. For a portion of the period, subaccounts may have limited expenses, without which returns would have been lower.
Variable annuities are long-term investments designed for retirement purposes. Putnam Hartford products are flexible-premium variable annuities issued by Hartford Life and Annuity Insurance Company, Simsbury, CT.
Putnam Allstate variable annuities are flexible-premium deferred variable annuities issued by Allstate Life Insurance Company (Allstate Life); underwritten by Allstate Distributors, L.L.C., both of Northbrook, IL; and sold through registered representatives or bank employees who are licensed insurance agents. Please check for availability in your specific state.
These policies have limitations and are sold by prospectus only. The prospectus contains details on the variable annuity, the subaccounts, contract features, fees, expenses, and other pertinent information.
Investors should carefully consider the investment objectives, risks, charges, and expenses of a fund before investing. For a prospectus containing this and other information for any variable annuity or variable life product that invests in Putnam Variable Trust funds, contact your financial advisor for a contract prospectus and prospectus for the underlying funds. You may also call Hartford at 1-800-521-0538 or Allstate at 1-800-390-1277. Read the prospectuses carefully before investing.
For the most recent month-end performance, please call Hartford at 1-800-521-0538 or Allstate at 1-800-390-1277.
The fund concentrates its investments in one region or in one sector and involves more risk than a fund that invests more broadly. Variable annuities are long-term investments designed for retirement purposes. Withdrawals prior to age 59 1/2 may be subject to a 10% IRS penalty.
Growth investing targets companies with above-average earnings that may be subject to price volatility if earnings expectations are not met.
Lipper is an industry research firm whose rankings are based on total return performance, vary over time, and do not reflect the effects of sales charges. Past performance is not indicative of future results.
Top 10 holdings as of 06/30/17
| Amgen | 5.88% |
|
|---|---|---|
| Merck | 5.55% |
|
| UnitedHealth Group | 5.09% |
|
| Jazz Pharmaceuticals | 4.92% |
|
| Becton Dickinson And | 4.71% |
|
| Novartis Ag | 4.21% |
|
| Bayer Ag | 4.06% |
|
| Johnson & Johnson | 3.93% |
|
| Biogen | 3.72% |
|
| Sanofi | 3.46% |
|
| Top 10 holdings, total: | 45.53% |
|
Equity Holdings as of 03/31/17
| AMGEN INC | 5.78% |
|---|---|
| MERCK & CO. INC. | 5.68% |
| CELGENE CORP | 5.27% |
| NOVARTIS AG-REG | 3.88% |
| JOHNSON & JOHNSON | 3.82% |
| BAYER AG-REG | 3.74% |
| BRISTOL-MYERS SQUIBB CO | 3.71% |
| ELI LILLY & CO | 3.60% |
| DANAHER CORP | 3.56% |
| SANOFI | 3.37% |
| BIOGEN INC | 3.29% |
| BECTON DICKINSON AND CO | 3.12% |
| ROCHE HOLDING AG-GENUSSCHEIN | 2.95% |
| JAZZ PHARMACEUTICALS PLC | 2.75% |
| ASTRAZENECA PLC | 2.73% |
| ALEXION PHARMACEUTICALS INC | 2.57% |
| BOSTON SCIENTIFIC CORP | 2.42% |
| PFIZER INC | 2.36% |
| SHIRE PLC | 2.34% |
| CR BARD INC | 2.14% |
| UNITEDHEALTH GROUP INC | 2.08% |
| GILEAD SCIENCES INC | 1.99% |
| MCKESSON CORP | 1.78% |
| AGILENT TECHNOLOGIES INC | 1.77% |
| CARDINAL HEALTH INC | 1.60% |
| WALGREENS BOOTS ALLIANCE INC | 1.53% |
| CIGNA CORP | 1.38% |
| GLAXOSMITHKLINE PLC | 1.31% |
| INTUITIVE SURGICAL INC | 1.30% |
| HUMANA INC | 1.27% |
| CHUGAI PHARMACEUTICAL CO LTD | 1.23% |
| SHIONOGI & CO LTD | 1.02% |
| BIOMARIN PHARMACEUTICAL INC | 0.89% |
| HENRY SCHEIN INC | 0.82% |
| STERICYCLE INC | 0.74% |
| PACIRA PHARMACEUTICALS INC | 0.73% |
| VERTEX PHARMACEUTICALS INC | 0.69% |
| GRIFOLS SA-ADR | 0.65% |
| PENUMBRA INC | 0.62% |
| AIN HOLDINGS INC | 0.56% |
| ILLUMINA INC | 0.51% |
| FRESENIUS MEDICAL CARE AG & | 0.42% |
| NIPPON SHINYAKU CO LTD | 0.42% |
| CHINA BIOLOGIC PRODUCTS INC | 0.41% |
| AUROBINDO PHARMA LTD | 0.39% |
| ASPEN PHARMACARE HOLDINGS LT | 0.33% |
| OVID THERAPEUTIC INC P/P 144A PCT 08.0000 | 0.32% |
| BIO-RAD LABORATORIES-A | 0.27% |
| ACLARIS THERAPEUTICS INC | 0.26% |
| ARRAY BIOPHARMA INC | 0.25% |
| CLOVIS ONCOLOGY INC | 0.25% |
| MEDICINES COMPANY | 0.25% |
| ACCELERON PHARMA INC | 0.21% |
| SINOPHARM GROUP CO-H | 0.10% |
| HTG MOLECULAR DIAGNOSTICS | 0.04% |
| NEURALSTEM INC SERIES J COMMON STOCK PURCHASE WARRANT | 0.00% |
Full Portfolio Holdings as of 03/31/17
| AMGEN INC | 5.78% |
|---|---|
| MERCK & CO. INC. | 5.68% |
| CELGENE CORP | 5.27% |
| NOVARTIS AG-REG | 3.88% |
| JOHNSON & JOHNSON | 3.82% |
| BAYER AG-REG | 3.74% |
| BRISTOL-MYERS SQUIBB CO | 3.71% |
| ELI LILLY & CO | 3.60% |
| DANAHER CORP | 3.56% |
| SANOFI | 3.37% |
| BIOGEN INC | 3.29% |
| BECTON DICKINSON AND CO | 3.12% |
| ROCHE HOLDING AG-GENUSSCHEIN | 2.95% |
| JAZZ PHARMACEUTICALS PLC | 2.75% |
| ASTRAZENECA PLC | 2.73% |
| ALEXION PHARMACEUTICALS INC | 2.57% |
| BOSTON SCIENTIFIC CORP | 2.42% |
| PFIZER INC | 2.36% |
| SHIRE PLC | 2.34% |
| CR BARD INC | 2.14% |
| UNITEDHEALTH GROUP INC | 2.08% |
| GILEAD SCIENCES INC | 1.99% |
| MCKESSON CORP | 1.78% |
| AGILENT TECHNOLOGIES INC | 1.77% |
| CARDINAL HEALTH INC | 1.60% |
| WALGREENS BOOTS ALLIANCE INC | 1.53% |
| CIGNA CORP | 1.38% |
| GLAXOSMITHKLINE PLC | 1.31% |
| INTUITIVE SURGICAL INC | 1.30% |
| HUMANA INC | 1.27% |
| CHUGAI PHARMACEUTICAL CO LTD | 1.23% |
| SHIONOGI & CO LTD | 1.02% |
| BIOMARIN PHARMACEUTICAL INC | 0.89% |
| HENRY SCHEIN INC | 0.82% |
| STERICYCLE INC | 0.74% |
| PACIRA PHARMACEUTICALS INC | 0.73% |
| VERTEX PHARMACEUTICALS INC | 0.69% |
| GRIFOLS SA-ADR | 0.65% |
| PENUMBRA INC | 0.62% |
| AIN HOLDINGS INC | 0.56% |
| ILLUMINA INC | 0.51% |
| FRESENIUS MEDICAL CARE AG & | 0.42% |
| NIPPON SHINYAKU CO LTD | 0.42% |
| CHINA BIOLOGIC PRODUCTS INC | 0.41% |
| AUROBINDO PHARMA LTD | 0.39% |
| ASPEN PHARMACARE HOLDINGS LT | 0.33% |
| OVID THERAPEUTIC INC P/P 144A PCT 08.0000 | 0.32% |
| BIO-RAD LABORATORIES-A | 0.27% |
| ACLARIS THERAPEUTICS INC | 0.26% |
| ARRAY BIOPHARMA INC | 0.25% |
| CLOVIS ONCOLOGY INC | 0.25% |
| MEDICINES COMPANY | 0.25% |
| ACCELERON PHARMA INC | 0.21% |
| SINOPHARM GROUP CO-H | 0.10% |
| HTG MOLECULAR DIAGNOSTICS | 0.04% |
| EUR/USD 06/21/2017 BANKAM | 0.01% |
| AUD/USD 04/19/2017 HSBCB | 0.00% |
| CHF/USD 06/21/2017 JPMCB | 0.00% |
| DKK/USD 06/21/2017 CITI | 0.00% |
| JPY/USD 05/17/2017 CSI-FX | 0.00% |
| NEURALSTEM INC SERIES J COMMON STOCK PURCHASE WARRANT | 0.00% |
| POUND STERLING CALL ACCOUNT | 0.00% |
Prior top 10 holdings
| Top 10 holdings as of 06/30/17 | |
|---|---|
| 1: Amgen | 5.88% |
| 2: Merck | 5.55% |
| 3: UnitedHealth Group | 5.09% |
| 4: Jazz Pharmaceuticals | 4.92% |
| 5: Becton Dickinson And | 4.71% |
| 6: Novartis Ag | 4.21% |
| 7: Bayer Ag | 4.06% |
| 8: Johnson & Johnson | 3.93% |
| 9: Biogen | 3.72% |
| 10: Sanofi | 3.46% |
| Holdings represent 45.53% of portfolio | |
| Top 10 holdings as of 05/31/17 | |
|---|---|
| 1: Merck | 5.77% |
| 2: Amgen | 5.42% |
| 3: Celgene Corp | 4.80% |
| 4: Becton Dickinson And | 4.68% |
| 5: Bayer Ag | 4.27% |
| 6: Novartis Ag | 4.24% |
| 7: Jazz Pharmaceuticals | 4.08% |
| 8: Johnson & Johnson | 3.90% |
| 9: UnitedHealth Group | 3.78% |
| 10: Sanofi | 3.66% |
| Holdings represent 44.60% of portfolio | |
| Top 10 holdings as of 04/30/17 | |
|---|---|
| 1: Amgen | 5.69% |
| 2: Merck | 5.51% |
| 3: Celgene Corp | 5.19% |
| 4: Jazz Pharmaceuticals | 4.45% |
| 5: Novartis Ag | 3.98% |
| 6: Bayer Ag | 3.97% |
| 7: Becton Dickinson And | 3.83% |
| 8: Bristol-Myers Squibb | 3.79% |
| 9: Johnson & Johnson | 3.74% |
| 10: Sanofi | 3.48% |
| Holdings represent 43.63% of portfolio | |
| Top 10 holdings as of 03/31/17 | |
|---|---|
| 1: Amgen | 5.78% |
| 2: Merck | 5.68% |
| 3: Celgene Corp | 5.27% |
| 4: Novartis Ag | 3.88% |
| 5: Johnson & Johnson | 3.82% |
| 6: Bayer Ag | 3.74% |
| 7: Bristol-Myers Squibb | 3.71% |
| 8: Eli Lilly | 3.60% |
| 9: Danaher Corp | 3.56% |
| 10: Sanofi | 3.37% |
| Holdings represent 42.41% of portfolio | |
Portfolio Composition as of 06/30/17
| Common stock | 95.97% |
|
|---|---|---|
| Cash and net other assets | 3.77% |
|
| Convertible bonds | 0.26% |
|
Portfolio allocations vary over time. The fund concentrates its investments in one region or in one sector and involves more risk than a fund that invests more broadly. Variable annuities are long-term investments designed for retirement purposes. Withdrawals prior to age 59 1/2 may be subject to a 10% IRS penalty.
Growth investing targets companies with above-average earnings that may be subject to price volatility if earnings expectations are not met.
Lipper is an industry research firm whose rankings are based on total return performance, vary over time, and do not reflect the effects of sales charges. Past performance is not indicative of future results.
Sales Charges/Fees
| Breakpoint | Sales Charge | Dealer Allowance | CDSC Liab |
|---|---|---|---|
| $0 - $0 | 0.00% | 0.00% | N |
The fund concentrates its investments in one region or in one sector and involves more risk than a fund that invests more broadly. Variable annuities are long-term investments designed for retirement purposes. Withdrawals prior to age 59 1/2 may be subject to a 10% IRS penalty.
Growth investing targets companies with above-average earnings that may be subject to price volatility if earnings expectations are not met.
‡ Lipper is an industry research firm whose rankings are based on total return performance, vary over time, and do not reflect the effects of sales charges. Past performance is not indicative of future results.